Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.61 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | GAPDH | P04406 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 3/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8494383 | 1.00 | HSPA5 (0.61) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL18952787 | 0.89 | ADK (0.65) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL18952790 | 0.89 | ADK (0.65) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL6305168 | 0.88 | HSPA8 (0.80) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL5362344 | 0.88 | HSPA8 (0.80) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL23498581 | 0.88 | HSPA8 (0.59) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL1144664 | 0.88 | NADK (0.60) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL6434241 | 0.88 | HSPA8 (0.80) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL1144665 | 0.88 | NADK (0.60) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL1144992 | 0.88 | ADK (0.66) | HSPA5HSPA8RXFP1GAPDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| WO-1999050447-A1 | METHOD AND NUCLEIC ACID COMPOUND FOR BREAKING DOWN NUCLEIC ACID MOLECULES SYNTHESIZED $i(IN VITRO) | MIRA DIAGNOSTIKA GMBH (DE) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | HSPA5 393/4885HSPA8 819/4885RXFP1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.